The NC-stat test is a quantitative point-of-care test that evaluates systemic neuropathies like diabetic peripheral neuropathy, a common disease affecting more than half of diabetics which may lead to foot ulcers and limb amputation.
This may be the boost that Neurometrix needs as it continues to shore up its flagging stock price. The company asked shareholders to approve a reverse stock split to boost its share price in April.
The companies plan to launch during the annual conference of the American Diabetes Association late in June, according to the release.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.